We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

56 hedge funds and large institutions have $108M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

8% less capital invested

Capital invested by funds: $117M → $108M (-$9.74M)

15% less funds holding

Funds holding: 6656 (-10)

22% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 18

39% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 23

Holders
56
Holders Change
-10
Holders Change %
-15.15%
% of All Funds
1.49%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
14
Increased
14
Reduced
18
Closed
23
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$14.2M
Franklin Resources
2
Franklin Resources
California
$9.77M -$7.23K -1,090 -0.1%
DA
3
DSC Advisors
Illinois
$9.51M +$25.3K +3,812 +0.3%
MMH
4
Menora Mivtachim Holdings
Israel
$8.58M
DM
5
Deerfield Management
New York
$8.14M +$2.21M +333,124 +35%
TCM
6
Tekla Capital Management
Massachusetts
$6.13M
PA
7
Perceptive Advisors
New York
$5.05M +$5.28M +795,000 New
OM
8
Opaleye Management
Massachusetts
$4.41M +$697K +105,000 +18%
DCM
9
Driehaus Capital Management
Illinois
$3.89M -$32.3K -4,871 -0.8%
SAM
10
Senzar Asset Management
New York
$3.8M -$6.64M -1,000,634 -63%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$3.62M +$76.7K +11,554 +2%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$3.5M -$446K -67,230 -11%
JGC
13
J. Goldman & Co
New York
$3.15M -$482K -72,633 -13%
SCM
14
Sio Capital Management
New York
$2.57M -$1.11M -167,254 -29%
BFA
15
BlackRock Fund Advisors
California
$2.45M -$3.96M -596,671 -61%
SFM
16
Sphera Funds Management
Israel
$2.17M
GPP
17
Great Point Partners
Connecticut
$1.75M +$1.82M +274,756 New
SM
18
Sabby Management
Florida
$1.61M -$44.4K -6,694 -3%
FHAM
19
Folger Hill Asset Management
New York
$1.51M
Baillie Gifford & Co
20
Baillie Gifford & Co
United Kingdom
$1.39M
Millennium Management
21
Millennium Management
New York
$1.25M +$550K +82,934 +72%
DCM
22
DAFNA Capital Management
California
$1.22M +$490K +73,896 +62%
UBS AM
23
UBS AM
Illinois
$942K -$3.41K -514 -0.3%
MC
24
Menta Capital
California
$924K +$217K +32,697 +29%
NC
25
Nexthera Capital
New York
$922K +$964K +145,250 New

FOMX Hedge Fund Activity: Q2 2016 in Review

56 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q2 2016, worth a combined $108M — down 8.3% from $117M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of FOMX and 14 opened new positions — a net loss of 9 holders — while 18 trimmed existing stakes and 14 added.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $5.28M. The largest seller was Senzar Asset Management, cutting an estimated $6.64M.

  • 56 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q2 2016, down from 66 in Q1 2016.
  • Funds reported $108M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q2 2016, down 8.3% quarter-over-quarter.
  • 14 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q2 2016 and 23 closed out, a net change of -9 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q2 2016 was Perceptive Advisors, an estimated $5.28M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q2 2016 was Senzar Asset Management, an estimated $6.64M sold.

Based on aggregated 13F filings for Q2 2016.